Stoke Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Stoke Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
  • Stoke Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$30M, a 10.2% decline year-over-year.
  • Stoke Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$117M, a 4.4% decline year-over-year.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$115M, a 9.98% decline from 2022.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$104M, a 21.3% decline from 2021.
  • Stoke Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$86.1M, a 62.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$117M -$30M -$2.77M -10.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$115M -$29.3M +$3.92M +11.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$118M -$28.4M -$3.68M -14.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$115M -$29.6M -$2.41M -8.88% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$112M -$27.2M -$86K -0.32% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$112M -$33.3M -$8.02M -31.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$104M -$24.7M +$105K +0.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$104M -$27.2M -$2.65M -10.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$102M -$27.1M -$4.47M -19.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$97.2M -$25.2M -$3.21M -14.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 -$94M -$24.8M -$7.97M -47.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$86.1M -$24.5M -$9.94M -68.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$76.1M -$22.7M -$8.97M -65.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$67.2M -$22M -$9.02M -69.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$58.1M -$16.8M -$5.09M -43.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$53M -$14.6M -$3.52M -31.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-09
Q3 2020 -$49.5M -$13.7M -$3.87M -39.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$45.7M -$13M -$4.57M -54.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$41.1M -$11.7M -$5.41M -85.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$35.7M -$11.1M -$6.53M -144% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$29.2M -$9.84M -$6.53M -197% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-09
Q2 2019 -$22.6M -$8.45M -$5.44M -181% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-09
Q1 2019 -$17.2M -$6.32M -$4.41M -231% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-09
Q4 2018 -$12.8M -$4.54M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-23
Q3 2018 -$3.32M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-23
Q2 2018 -$3.01M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-23
Q1 2018 -$1.91M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.